/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

S

Susanne Hartz

Eli Lilly (United States)(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

44

Papers

676

Citations

11

h-index

11

i10-index

Susanne Hartz is an academic researcher from Eli Lilly (United States). The author has contributed to research in topics: Inflammatory Bowel Disease & Health Systems, Economic Evaluations, Quality of Life & Psoriasis: Treatment and Pathogenesis. The author has an h-index of 11, co-authored 38 publications.

ORCID: 0000-0001-8475-0260

Research Topics

Inflammatory Bowel Disease Health Systems, Economic Evaluations, Quality of Life Psoriasis: Treatment and Pathogenesis Microscopic Colitis Spondyloarthritis Studies and Treatments

Papers by this author

works

Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis

2020 · RMD Open · 82 citations

https://doi.org/10.1136/rmdopen-2019-001117

Adeline Ruyssen‐Witrand Richard Perry Clare J. Watkins George Braileanu

Evaluación de la eficiencia de los tratamientos biológicos en la psoriasis moderada a grave en España: análisis de coste por número necesario a tratar (NNT)

2019 · Actas Dermo-Sifiliográficas · 16 citations

https://doi.org/10.1016/j.ad.2018.10.017

Mercedes Núñez Teresa Huete P. de la Cueva J.A. Sacristán

Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis

2024 · Advances in Therapy · 16 citations

https://doi.org/10.1007/s12325-024-03003-8

Axel Dignaß Claire Ainsworth Susanne Hartz Niels Dunnewind

Elicitation of health state utilities associated with varying severities of flares in Systemic Lupus Erythematosus

2015 · Health and Quality of Life Outcomes · 9 citations

https://doi.org/10.1186/s12955-015-0262-0

Catherine Pollard Susanne Hartz Soyi Liu Leage M Paget

Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK

2020 · PharmacoEconomics - Open · 8 citations

https://doi.org/10.1007/s41669-020-00202-1

Bernd Schweikert Chiara Malmberg Örjan Åkerborg Gayathri Kumar

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain

2020 · BMJ Open · 7 citations

https://doi.org/10.1136/bmjopen-2019-032552

Bernd Schweikert Chiara Malmberg Mercedes Núñez Tatiana Dilla

Research topics

topics

Inflammatory Bowel Disease

Health Systems, Economic Evaluations, Quality of Life

Psoriasis: Treatment and Pathogenesis

Microscopic Colitis

Spondyloarthritis Studies and Treatments

Chat about Author

Papers

Chat

Click to start Chat